We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.36B
1-Year Est. Return 204.53%
This Fund
S&P 500
This Quarter Est. Return
+69.67%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$2.08B
AUM Growth
+$395M
Cap. Flow
-$319M
Cap. Flow %
-15.3%
Top 10 Hldgs %
80.63%
Holding
43
New
6
Increased
4
Reduced
3
Closed
13

Top Buys

Rank Stock Value
1
ORIC icon
Oric Pharmaceuticals
ORIC
+$53.8M
2
BBOT
BridgeBio Oncology
BBOT
+$29.4M
3
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$20.2M
4
MBX
MBX Biosciences
MBX
+$13M
5
AQST icon
Aquestive Therapeutics
AQST
+$11.3M

Top Sells

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$197M
2
ITOS
iTeos Therapeutics
ITOS
+$107M
3
JANX icon
Janux Therapeutics
JANX
+$34M
4
KURA icon
Kura Oncology
KURA
+$23.7M
5
AKRO
Akero Therapeutics
AKRO
+$23.5M

Sector Composition

Rank Sector Weight
1 Healthcare 99.79%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PEPG icon
26
PepGen
PEPG
$131M
$3.7M 0.18%
+800,000
New +$1.29M
NUVB.WS
27
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$3.56M 0.17%
963,333
– –
VYGR icon
28
Voyager Therapeutics
VYGR
$187M
$3.13M 0.15%
670,303
-3,247,243
-83% -$11.7M
CMPS
29
Compass Pathways
CMPS
$1.52B
$1.52M 0.07%
+265,137
New +$1.19M
SRZNW icon
30
Surrozen Inc Warrant
SRZNW
$75.6K
$859K 0.04%
66,665
– –
ADAP
31
DELISTED
Adaptimmune Therapeutics
ADAP
– –
-27,404,070
Closed -$6.57M
AKRO
32
DELISTED
Akero Therapeutics
AKRO
– –
-440,000
Closed -$23.5M
DAWN
33
DELISTED
Day One Biopharmaceuticals
DAWN
– –
-862,068
Closed -$5.6M
HLVX
34
DELISTED
HilleVax
HLVX
– –
-2,420,243
Closed -$4.82M
ITOS
35
DELISTED
iTeos Therapeutics
ITOS
– –
-10,688,978
Closed -$107M
JANX icon
36
Janux Therapeutics
JANX
$950M
– –
-1,469,818
Closed -$34M
MGNX icon
37
MacroGenics
MGNX
$254M
– –
-1,602,717
Closed -$1.94M
PCRX icon
38
Pacira BioSciences
PCRX
$1.04B
– –
-457,471
Closed -$10.9M
QURE icon
39
CALL
uniQure
QURE
$2.63B
– –
-135,000
Closed -$1.88M
REPL icon
40
Replimune Group
REPL
$724M
– –
-850,341
Closed -$7.9M
VRNA
41
DELISTED
Verona Pharma
VRNA
– –
-200,000
Closed -$18.9M
TECX
42
Tectonic Therapeutic
TECX
$578M
– –
-935,121
Closed -$18.6M
WHWK
43
Whitehawk Therapeutics
WHWK
$183M
– –
-1,091,417
Closed -$2.04M
1
2

Similar funds

HFM
Harvest Fund Management Beijing, China $2.35B AUM 49.85% 1-Year Est. Return
CC
Capital Counsel New York $2.35B AUM 21.34% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
ROIC
Route One Investment Company San Francisco, California $2.35B AUM 11.7% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
G
GenTrust Miami, Florida $2.34B AUM 18.43% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return
CIP
Cornerstone Investment Partners Atlanta, Georgia $2.38B AUM 32.49% 1-Year Est. Return

EcoR1 Capital's Q3 2025 Portfolio in Review

As of Q3 2025, EcoR1 Capital held 43 positions worth $2.08B, up 23% from $1.69B the previous quarter. Its ten largest holdings account for 81% of the portfolio.

EcoR1 Capital withdrew a net $319M in Q3 2025, closing 13 positions and reducing 3 holdings. Its most notable exit was iTeos Therapeutics, an estimated $107M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

Against the trend, EcoR1 Capital opened a new position in BridgeBio Oncology worth $32.7M.

  • EcoR1 Capital's largest Q3 2025 buy was BridgeBio Oncology: 2,823,126 shares worth $32.7M.
  • EcoR1 Capital added most to Oric Pharmaceuticals in Q3 2025, an estimated $53.8M increase.
  • EcoR1 Capital's biggest Q3 2025 reduction was Apellis Pharmaceuticals, cutting an estimated $197M.
  • EcoR1 Capital fully exited iTeos Therapeutics in Q3 2025, selling an estimated $107M.
  • EcoR1 Capital's ten largest holdings make up 81% of its $2.08B portfolio in Q3 2025.
  • EcoR1 Capital opened 6 new positions and closed 13 in Q3 2025.
  • EcoR1 Capital's portfolio value rose 23% quarter-over-quarter to $2.08B.

Based on EcoR1 Capital's 13F filing for Q3 2025, filed 14 Nov 2025.